Press Releases
Search
-
30 Jul 2024
bioMérieux Receives 10 Clinical Laboratory Awards for Excellence in Customer Satisfaction, System Performance and Service
bioMérieux, a world leader in in vitro diagnostics, received 10 IMV ServiceTrak™ Clinical Laboratory Awards today in the categories of microbial identification and susceptibility testing, Blood Culture, Immunoassay, and Molecular Diagnostics. The awards symbolize bioMérieux’s high-quality comprehensive customer service and system performance.
-
26 Jun 2024
SITES - Press Release
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).
-
21 Jun 2024
bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™
bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
-
28 May 2024
SITES - Press Release
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.
-
23 May 2024
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
The Malawi Ministry of Health, bioMérieux, and Pfizer today announced a collaboration to advance Malawi’s first multisectoral initiative which aims to build public sector antimicrobial stewardship (AMS) capacity in infection prevention and control, diagnostics, surveillance, and to guide the appropriate use of antibiotics.
-
09 Apr 2024
SITES - Press Release
bioMérieux presents its new 5-year strategic plan and its targets for profitable growth
bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.
-
09 Apr 2024
SITES - Press Release
First-quarter 2024 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2024.
-
05 Apr 2024
SITES - Press Release
bioMérieux and Mérieux NutriSciences partner with key food industry players to launch a new collaborative data-driven model
bioMérieux and Mérieux NutriSciences jointly announce the launch of a new data-driven Trusted Third Party initiative, built with a group of global food industry partners to foster safe industry collaboration as well as better anticipate and prevent food safety risks.
-
27 Mar 2024
SITES - Press Release
Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel
Marcy-l’Étoile (France), March 27th, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laborato...
-
14 Mar 2024
SITES - Press Release
bioMérieux – 2023 Financial Results
Today bioMérieux released its 2023 financial results. Consolidated sales amounted to €3,675 million in 2023, up 6.6% like-for-like from €3,589 million in the prior year period.
-
08 Jan 2024
Mergers & Acquisitions
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.
-
06 Dec 2023
Antimicrobial Resistance
Texas Children's Hospital Joins the bioMérieux Global Network of Antimicrobial Stewardship Centers of Excellence
Texas Children’s Hospital, a nonprofit health care organization, is the newest facility inducted into the bioMérieux global Antimicrobial Stewardship Center of Excellence program. bioMérieux, a world leader in in vitro diagnostics, is proud to partner with Texas Children’s.
-
26 Oct 2023
Financial Information
bioMérieux - Third-Quarter 2023 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023. Consolidated sales amounted to €2,668 million for the first nine months of 2023.
-
19 Oct 2023
Financial Information
bioMérieux makes strategic investment in Oxford Nanopore
Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.
-
13 Oct 2023
Business & Solutions
bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1)
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.